What Is the Difference Between Critical, Major and Minor Defects in Injectables?

Critical, major and minor defects in pharma injectables are three risk classes used to sort defects found during the visual inspection of vials, ampoules, prefilled syringes and cartridges. A critical defect can harm the patient or break sterility, such as a cracked vial. A major defect affects function, dose or usability, such as underfill. A minor defect is cosmetic only, such as a light scratch on the outer glass.

The class you assign decides the AQL limit, how many defects are allowed in the QA sample, and whether the batch can be released.

	Critical	Major	Minor
Risk	Patient harm, sterility or seal failure	Function, dose or usability affected	Cosmetic only
Injectable example	Cracked vial, missing stopper	Underfill, raised stopper	Scratch on outer glass
Typical AQL (USP <1790>)	0.010–0.10%	0.10–0.65%	1.0–4.0%
Usual accept number	0	Small number, per sampling table	Higher number, per sampling table

This guide covers sterile injectables, where the rules are strictest. A short bonus section also explains how the same classes apply to tablets, capsules and packaging.

What Are Critical, Major and Minor Defects in Pharma?

Defect classification means placing every possible product defect into a risk class based on its impact on the patient and the product. The classes are written in a defect library (defect catalogue), which is part of the visual inspection SOP. USP <1790> uses three classes: critical, major and minor.

• Critical: Can put the patient’s health at risk, or shows that sterility or container closure integrity (CCI) is lost.
• Major: Does not directly harm the patient, but can change the usability, function or content of the product (for example, the dose delivered).
• Minor: Does not affect safety, function or content. It lowers how the product looks.

Many companies also keep a fourth level, cosmetic imperfection or “observation”, for marks too small to count as a defect. This is fine if your SOP defines it clearly.

Why it matters: injectables bypass the body’s natural defences. A crack, a leaking seal or a foreign particle can reach the bloodstream, eye or spinal fluid directly. A clear defect library gives QA a fixed basis for release decisions and gives every shift and site the same rules. It also lets you answer the question auditors from USFDA, EU agencies and CDSCO commonly ask: why is this defect in this class?

What Is a Critical Defect in Injectables?

A critical defect is a defect that can seriously harm the patient or shows that the container is no longer sterile or sealed. In AQL sampling, the accept number for critical defects is normally zero. One critical defect in the QA sample fails the sample and starts an investigation.

Common critical defects in injectables:

• Crack or chip in the glass in the product-contact area (vial body, ampoule neck, syringe barrel)
• Missing stopper, missing seal or missing plunger
• Badly crimped or broken aluminium seal that may allow leakage
• Leaking container or any visible loss of container closure integrity
• Glass particles or glass delamination flakes (lamellae) in the solution
• Fibres, hair or particles of biological origin in the solution
• Signs of microbial growth, such as unexpected turbidity or clumps
• Wrong product, wrong strength or missing label
• Empty container
• Prefilled syringe needle defects, such as a bent needle or missing needle shield

Typical AQL range: 0.010–0.10% (USP <1790>), with an accept number of 0.

Practical tip: Do not mark every particle as critical by default. The class should depend on what the particle is, where it came from and the route of administration. See the risk-based method below.

What Is a Major Defect in Injectables?

A major defect is a defect that does not directly harm the patient but can affect the function, dose, usability or processing of the product. It may cause a failed injection, a wrong dose or a complaint. Typical AQL for major defects is 0.10–0.65%, and 0.65% is the most common choice.

Common major defects in injectables:

• Fill volume or fill height outside specification (but not empty)
• Stopper raised or damaged, with container integrity still intact
• Dented or deformed container that may jam on a filling, labelling or auto-injector line
• Solution discoloured beyond its colour specification
• Visible non-biological particles (rubber, stainless steel, plastic), in many risk assessments
• Lyophilised cake collapse or meltback that may affect reconstitution (see our guide on how to inspect lyophilized vials for cake defects)
• Smudged printing that makes the batch number or expiry hard to read
• Plunger stopper in the wrong position in a prefilled syringe

Why 0.65% is common: USP <790> requires acceptance sampling after 100% inspection using ANSI/ASQ Z1.4 (or ISO 2859-1), General Inspection Level II, with an AQL of 0.65% for visible particulates. Many companies therefore set visible particles at major or stricter.

What Is a Minor Defect in Injectables?

A minor defect is a cosmetic flaw that does not affect the safety, sterility, function or content of the product. It usually comes from the production process and lowers how the product looks. Typical AQL for minor defects is 1.0–4.0%, with 2.5% widely used.

Common minor defects in injectables:

• Light scratches or scuffs on the outer glass
• Small airlines or “stones” in the glass wall that do not reduce strength
• Slight label misalignment or wrinkle, with all text readable
• Small dent on the flip-off cap
• Fibre or dust on the outside of the container or needle shield, with no product contact
• Slight cake shrinkage in lyo vials that does not affect reconstitution

Minor defects do not affect safety, but they still matter. Export customers and hospital buyers often complain about cosmetic issues, and a rising minor-defect trend can signal a process problem before it becomes a major one.

Container-Wise Examples for Injectables

Different containers fail in different ways. Build your defect library for each container format. Do not copy one generic list.

Container	Critical	Major	Minor
Glass vial	Crack at heel or shoulder, missing stopper	Raised stopper, underfill	Outer scuff, small cap dent
Ampoule	Cracked or open tip, crack at neck	Wrong fill height, deformed tip	Faint printing mark
Prefilled syringe	Cracked barrel, missing needle shield, bent needle	Plunger out of position, air bubble beyond spec	Fibre on outer barrel
Lyophilised vial	Crack, missing stopper, foreign particle on cake	Cake collapse, meltback	Slight cake shrinkage
Cartridge	Crack, leaking septum	Plunger out of position	Label wrinkle

Bonus: How Do These Classes Apply to Tablets, Capsules and Packaging?

The same three classes are used for oral solid dosage forms and packaging. Patient risk still sets the class, but the defect types differ.

Class	Tablets and capsules	Blister and secondary packaging
Critical	Foreign tablet or capsule mixed in, wrong debossing, embedded foreign particle	Wrong or missing label, missing or illegible batch number or expiry, hole in blister foil or failed leak test
Major	Broken or capped tablet, empty or split capsule	Empty blister pocket, crushed product in pocket, missing perforation
Minor	Small spots, chipping or pitting on the tablet surface	Minor print smudge with text readable, slight carton scuff

AQL values for oral solids and packaging are set in each company’s SOP and are usually looser than for injectables. Base them on your own risk assessment, not on a number copied from another site.

How Does Defect Class Decide the AQL Sampling Plan?

The defect class decides the AQL. AQL decides how many defects are allowed in the QA sample. Critical defects get the lowest AQL and usually zero accept. Major defects get a moderate AQL, often 0.65%. Minor defects get the highest, often 2.5%. If any class crosses its reject number, the batch is not released until it is investigated.

100% inspection vs AQL inspection

Injectable batches go through two checks:

1. 100% inspection: Every unit is checked, by trained inspectors, a semi-automated system or an automated inspection machine. Defective units are removed.
2. AQL inspection: QA then takes a statistical sample and inspects it again. This confirms the 100% inspection worked.

AQL (Acceptable Quality Limit) is the highest defect rate accepted as a process average. It is applied through sampling tables in ANSI/ASQ Z1.4 or ISO 2859-1. These tables give a sample size and accept/reject numbers based on batch size.

Visual inspection finds defects only with a certain probability, so some defective units can still remain after 100% inspection. AQL sampling checks that the number left behind is within limits.

Worked example: a batch of 50,000 vials

Under ANSI/ASQ Z1.4, single sampling, normal inspection, General Inspection Level II, a lot of 35,001–150,000 units gives code letter N and a sample of 500 units.

Class	AQL	Accept	Reject
Critical	Zero accept	0	1
Major	0.65%	7	8
Minor	2.5%	21	22

In these 500 vials, one critical defect fails the sample. Up to seven major and twenty-one minor defects are still acceptable. If a limit is crossed, raise a deviation, find the root cause and follow your SOP. That usually means 100% re-inspection under defined, justified conditions.

AQL sampling checks your 100% inspection. It does not replace it.

Inspection conditions that affect classification

How well inspectors spot and classify defects depends on the inspection conditions. USP <790> sets the manual inspection reference:

• Light intensity at the inspection point of 2,000–3,750 lux
• Inspection against both a black and a white background
• About 5 seconds per background for each unit
• No magnification, except normal vision correction

Automated inspection machines must be shown to perform at least as well as this manual method. That is usually shown with a Knapp test (see below).

What Do USP, EU GMP Annex 1, FDA and Revised Schedule M Say?

Guidance	What it means for defect classification
USP <790> Visible Particulates in Injections	100% inspection of all parenteral units, then acceptance sampling at AQL 0.65% (Z1.4 / ISO 2859-1, Level II). Product must be “essentially free” of visible particles.
USP <1790> Visual Inspection of Injections	Explains critical, major and minor classes, typical AQL ranges, inspector qualification and a lifecycle approach. See our explainer on USP <790> and <1790>.
EU GMP Annex 1 (2022)	Every filled sterile container must be inspected individually. It also requires qualified inspectors, validated automated systems, and trending of defect types and rates.
FDA draft guidance (Dec 2021): Inspection of Injectable Products for Visible Particulates	Asks for a holistic, risk-based particle control programme. Says meeting the USP standard alone is generally not enough to meet CGMP.
Revised Schedule M (India)	Notified by G.S.R. 922(E). Large units with turnover above ₹250 crore had to comply from mid-2024. MSMEs got extended time up to 31 December 2025. A DCGI circular dated 7 August 2024 asked sterile and vaccine makers to do a gap analysis against revised Schedule M and WHO TRS 1044 Annex 2.

For Indian manufacturers: revised Schedule M is now in force for both large units and MSMEs. Your defect library must satisfy CDSCO and state drug inspectors and, if you export, USFDA, EU or WHO-PQ inspectors as well. One library built to USP <790>/<1790> and Annex 1 usually works for all of them.

How Do You Classify a Defect? A 5-Step Risk-Based Method

Classify a defect by its risk to the patient, not by how it looks. A 2025 paper by Mahler and co-authors in Pharmaceutics uses an FMEA-style score: Severity × Probability of Occurrence × Probability of Detection. In their model, 51 or above is critical, above 25 up to 50 is major, above 5 up to 25 is minor, and 5 or below is cosmetic.

You can adapt this into five steps:

1. List every possible defect for each container, closure and product. Use past rejects, complaints, supplier data and line trials.
2. Rate severity for the patient. Look at the route of administration (IV, intrathecal and ophthalmic are higher risk), the patient group (neonates, ICU) and the dose.
3. Check impact on sterility and CCI. A defect that can break the sterile barrier is critical, however small it looks. Confirm doubtful cases with container closure integrity testing.
4. Rate detectability. Hard-to-see defects, such as small particles or hairline cracks, need tighter controls, better inspection conditions or extra tests.
5. Document, approve and train. Write the reason for each class in the defect library. Get QA approval, add photos and physical defect samples, and train inspectors on them.

Grey-zone defects: how to decide

Defect	Usual class	Reason
Fibre or hair in solution	Critical	May be of biological origin; sterility concern
Glass particle or lamellae	Critical	Shows container failure; embolism risk
Rubber or metal particle	Often major	Non-biological; depends on size, route and risk assessment
Stopper slightly raised, seal intact	Major	Handling or function risk; confirm CCI
Scratch on outer glass	Minor	No product contact; cosmetic
Deep scratch that weakens glass	Major or critical	Can lead to breakage in transit or use

Common Mistakes in Defect Classification

• Marking everything critical. It looks safe, but it raises false rejects, wastes good product and hides real trends.
• Underrating particles. Calling all particles minor or cosmetic is a common audit finding. Particle class must be backed by a risk assessment.
• Different rules on different lines or sites. If Line 1 calls a raised stopper major and Line 2 calls it minor, your trend data is useless.
• Written definitions only. Without photos and physical samples, inspectors judge the same defect differently.
• Never updating the library. A new container, a new component supplier, a complaint or an audit finding should trigger a review.
• Relying only on visual checks for leaks. Visual inspection cannot find every integrity failure. High-risk defects need CCIT support.

How Are Defect Classes Used in Inspector Qualification and Knapp Tests?

Inspectors and automated machines are qualified using defect sets: containers with known critical, major and minor defects mixed with good units. USP <1790> and EU GMP Annex 1 expect this qualification. The Knapp test compares manual and automated detection rates on the same units to show the machine performs at least as well as qualified inspectors.

A good defect challenge set should:

• Match your actual container and product type (clear, amber, lyophilised, suspension)
• Cover every class in your defect library, especially critical defects
• Include particles near the detection limit, not only easy-to-see ones
• Include good units, so false rejects are also measured
• Come with documentation and a defined re-certification schedule

Key Takeaways

• Critical defects can harm patients or break sterility. Typical AQL is 0.010–0.10%, with zero accepted in the sample.
• Major defects affect function, dose or usability. Typical AQL is 0.10–0.65%. USP <790> sets 0.65% for visible particles.
• Minor defects are cosmetic only. Typical AQL is 1.0–4.0%.
• Classify by patient risk, route of administration and impact on container closure integrity, not by appearance.
• AQL sampling checks 100% inspection. It never replaces it.
• In India, revised Schedule M now applies to all manufacturers. A documented defect library, real defect samples and qualified inspectors are basic audit requirements.

Frequently Asked Questions

What is AQL in pharma?

AQL (Acceptable Quality Limit) is the highest defect rate accepted as a process average when a batch is sampled. Sampling tables such as ANSI/ASQ Z1.4 or ISO 2859-1 use the AQL and the batch size to set the sample size and the accept/reject numbers.

What is the AQL for critical defects in injectables?

USP <1790> gives a typical range of 0.010–0.10% for critical defects. Most companies set the accept number at zero, so one critical defect in the sample fails it and starts an investigation.

Are visible particles a critical or a major defect?

It depends on the risk assessment. Glass, fibres and particles of biological origin are usually critical. Non-biological particles such as rubber or metal are often major. USP <790> sets an AQL of 0.65% for visible particles in the acceptance sample.

Is a cracked vial always a critical defect?

A crack in the product-contact area, or one that breaks container closure integrity, is critical because it can cause contamination or leakage. A surface mark that does not go through the glass or reduce its strength may be classed as minor or major after assessment.

What happens if a batch fails the AQL test?

The batch is not released. QA raises a deviation, investigates the root cause and decides the next step under the SOP. This is often a 100% re-inspection under defined and justified conditions, followed by a fresh AQL sample.

Does AQL inspection replace 100% visual inspection?

No. USP <790> and EU GMP Annex 1 require every filled injectable container to be inspected. AQL sampling comes after this as a statistical check that the 100% inspection worked.

Final Word

Getting critical, major and minor defects in pharma injectables right comes down to three things. Classify each defect by patient risk, link each class to the right AQL, and write down the reason so it holds up in an audit. Then test your inspectors and machines on real defect samples that match your own containers.